Traditional forms of treatment - tablets and oral suspension – are not used in patients with angle-closure glaucoma or with narrow anterior chamber angles.
Oxybutynin is not used in patients with myasthenia gravis, non-persistent cardiovascular status in acute hemorrhage. These two forms of the medicine are also contraindicated in patients with obstructive uropathy, obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony (in attenuated patients), megacolon, toxic megacolon complicating ulcerative colitis, or severe colitis. Oxybutynin extended-release tablets and transdermal system are not used in patients with: • Increased risk of urinary retention; • Increased risk of gastric retention; • Decreased gastrointestinal motility conditions; • Uncontrolled angle-closure glaucoma. Oxybutynin in all dosage forms is not used in patients with allergic reactions or known hypersensitivity to oxybutynin or any ingredient in the formulations.